Abstract
Following radical nephrectomy, systemic failure rates are higher than 50% in patients with locally advanced renal cell carcinoma. Given the lack of curative systemic therapies for patients with metastatic disease, the development of an effective adjuvant therapy is a critical unmet need. The recent randomized, double-blind, phase III ASSURE trial failed to demonstrate a benefit for 1 year of either adjuvant sorafenib or sunitinib versus placebo in …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
